Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEREOPAC: iHD-SBRT with chemotherapy for borderline resectable pancreatic cancer
NCT05083247Phase 2Recruiting
- Sponsor
- Erasmus Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of mFOLFIRINOX, gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Erasmus Hospital. Started Mar 2023; status: recruiting.
02
Drugs
mFOLFIRINOXgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05083247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083247.